Crenezumab Phase II cognition data in Alzheimer's disease presented
16.July 2014 08:00 CET
- Two phase II studies in people with mild-to-moderate Alzheimer's disease over 18 months and a total of 522 patients
- The proof of concept ABBY study met overall objective of estimating treatment effects and demonstrated positive trends in cognitive endpoints over time, although the study did not meet its co-primary endpoints
- Larger effects seen in patients with mild disease on high-dose of crenezumab intravenously
- Acceptable risk benefit profile
- Next steps to be determined by Roche following further analysis of data